Parkinson Disease

Jim Eubanks, PhD, national director of medical affairs at Octave, provided thoughts on the company’s $10 million grant from The Michael J. Fox Foundation for Parkinson’s Research and highlighted the importance of awareness for movement disorders like Parkinson disease.

The chief executive officer at Parkinson & Movement Disorder Alliance and the president at PD Avengers discussed the importance of awareness in movement disorders and the challenges that patients still face in getting access to treatments for improved quality of life. [WATCH TIME: 12 minutes

The professor of neurology at the University of Toronto provided insight on several prominent targets in the brain for deep brain stimulation, including emerging ones that may not gain as much attention. [WATCH TIME: 3 minutes]

Apart from the small pump system, which was preferred by the patients, the study found no clear advantage of levodopa-entacapone-carbidopa to levodopa-carbidopa intestinal gel.

A recent study suggests that palliative education and telehealth improve quality of life and advance care planning among patients with Parkinson disease and related disorders.

If successful, the study has potential implications for future surgical outcomes and patient experience among those with Parkinson disease.

Standardizing protocols and incorporating objective diagnostics and telemedicine can enhance care for patients with PD and alleviate the burden on healthcare systems.

The trial will feature 60 individuals with early-stage Parkinson disease who will be randomly assigned 1:1 to either daily CVN424 or placebo for a 12-week treatment period.

Carbidopa levodopa enteral suspension for Parkinson disease demonstrated cost-effectiveness compared to standard care, with an incremental cost-effectiveness ratio of $7711/QALY in a real-world study.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease.

In a small-scale trial, patients with Parkinson disease on accelerated theta-burst transcranial ultrasound demonstrated higher motor evoked potentials than those on sham, with no statistically significant changes in MDS-UPDRS-III scores.

The data suggest that central nervous system-derived extracellular vesicles in the blood will likely play a key role in biomarker development, especially for patients with Parkinson disease, in the coming years.

In animal models, HL192 showed disease-modifying effects, as demonstrated through improvements in behavioral deficits.

Among football players, odds of having a parkinsonism or Parkinson disease diagnosis were greater with more seasons and higher level of football play.

PRO-PD showed good 6-month test-retest reliability, as well as good convergent validity between other widely used validated scales of PD.

During the progression of the movement disorder, older patients with Parkinson disease may see changes in their insulin-like growth factor and serum homocysteine indices but a potential therapy could improve these factors.

Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic, provided comment on a recently published randomized controlled trial assessing the therapeutic potential of an augmented reality program for postural instability and gait dysfunction in Parkinson disease.

After Supernus met with the FDA earlier this year, the company believes it has addressed the agency’s requests mentioned in its complete response letter delivered in October 2022.

The senior vice president and chief scientific officer of the Parkinson’s Foundation discussed a recently published Medicare claims analysis that highlighted significant issues with access to proper care for patients with Parkinson disease. [WATCH TIME: 4 minutes]

The senior vice president and chief scientific officer of the Parkinson’s Foundation provided perspective on the reasons for the lack of mental health specialists in Parkinson disease care and the complexities behind treating depression. [WATCH TIME: 4 minutes]

The professor of neurology and resident program director at MedStar Georgetown University Hospital discussed how Parkinson disease motor fluctuations are managed amid new, novel technologies incorporated in the field. [WATCH TIME: 4 minutes]

Although research supports the use of physical therapy as an effective treatment for Parkinson disease, implementation factors including type, timing, frequency, and durability of outcomes remain mainly untouched.

Virginia Gao, MD, PhD, a movement disorders fellow at Weill Cornell Medicine, discussed several topics related to the use of biomarkers in the prodromal stages of neurodegenerative disorders like Parkinson disease.

The movement disorder specialist at Cambridge University Hospitals NHS Foundation Trust talked about a patient with treatment-resistant Parkinson disease who experienced significant improvement in motor symptoms after using a vibrational therapy. [WATCH TIME: 8 minutes]

Because its gut-acting and gut-restricted, the safety profile of DGX-001 was considered advantageous in comparison to traditional neuropsychiatric therapies.